Tofacitinib
- PDF / 181,642 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 61 Downloads / 152 Views
1 S
Tofacitinib Cytomegalovirus colitis, Clostridium difficile colitis, oral candidiasis and unspecified respiratory infection: 4 case reports
In an investigator-initiated, real clinical practice study, involving 24 patients (aged 18-65 years) with active ulcerative colitis, 4 patients [sexes and exact ages not stated] were described, who developed cytomegalovirus (CMV) colitis, Clostridium difficile colitis, oral candidiasis or unspecified respiratory infection during treatment with tofacitinib for ulcerative colitis [durations of treatments to reactions onsets and outcomes not stated]. All the patients, who were diagnosed with ulcerative colitis, started receiving oral tofacitinib 10mg twice daily until week 8 of the follow-up. The patients developed CMV colitis (n=1), Clostridium difficile colitis (n=1), oral candidiasis (n=1) or unspecified respiratory infection (n=1) due to tofacitinib. Kolar M, et al. Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice. Gastroenterologie a Hepatologie 74: 28-34, No. 1, Feb 803502672 2020. Available from: URL: http://doi.org/10.14735/amgh202028
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
